Kerim Erhan Palaoğlu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kerim Erhan Palaoğlu has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Osman Oğuz
American Hospital, Clinical Biochemistry, Istanbul, Turkey
2 shared publications - Said Incir
Department of Biochemistry, Medical School of Cerrahpasa, Istanbul University, Istanbul, Turkey
2 shared publications - Arzu Baygul
Department of Biostatics, Koç University School of Medicine, İstanbul, Türkiye
1 shared publication - Aydin Turkmen
Division of Nephrology, İstanbul University İstanbul Faculty of Medicine, İstanbul, Türkiye
1 shared publication - Başak Akyollu
Prof. Munci Kalayoglu, M.D. Organ Transplant Center, Koc University Hospital, Istanbul, Türkiye
1 shared publication - Berna Yelken
Organ Transplantation Center, Koc University Hospital, Istanbul, Turkey
1 shared publication
Latest Publications
- 21 September 2026
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
Responsibility without a map: defining oversight of automated result release in the medical laboratory
Laboratory specialists have been assigned responsibility for algorithmically assisted reporting without an operational definition of what responsible oversight means. Results pass largely through rule-based approval systems, and increasingly through probabilistic models, yet the obligation attached to the specialist’s name on the report has never been restated. Taking the position of the specialist who signs rather than the regulator who writes, and starting from requirements the discipline already accepts, we derive four capacities on which approving a result depends: designing the release logic and making it legible, anticipating where it will fail, correcting it when it does, and detecting that it has failed. These are not properties of a technology. Every system sits on a gradient whose position depends less on whether it uses machine learning than on what the laboratory has recorded about it. The oversight problem therefore did not arrive with machine learning but with automation, and most of what is now asked of laboratories in respect of artificial intelligence was already owed in respect of autoverification. Mapped against the four capacities, current frameworks require documentation and change control, address detection only in general terms, and nowhere require a laboratory to state in advance which results may be released without human review. Where laboratories have been asked, they report holding few of the records by which compliance could be shown. We propose a set of such records, identify what a single laboratory can and cannot reasonably do, and set out the questions the profession has not yet answered.
- 21 September 2026
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
Responsibility without a map: defining oversight of automated result release in the medical laboratory
Laboratory specialists have been assigned responsibility for algorithmically assisted reporting without an operational definition of what responsible oversight means. Results pass largely through rule-based approval systems, and increasingly through probabilistic models, yet the obligation attached to the specialist’s name on the report has never been restated. Taking the position of the specialist who signs rather than the regulator who writes, and starting from requirements the discipline already accepts, we derive four capacities on which approving a result depends: designing the release logic and making it legible, anticipating where it will fail, correcting it when it does, and detecting that it has failed. These are not properties of a technology. Every system sits on a gradient whose position depends less on whether it uses machine learning than on what the laboratory has recorded about it. The oversight problem therefore did not arrive with machine learning but with automation, and most of what is now asked of laboratories in respect of artificial intelligence was already owed in respect of autoverification. Mapped against the four capacities, current frameworks require documentation and change control, address detection only in general terms, and nowhere require a laboratory to state in advance which results may be released without human review. Where laboratories have been asked, they report holding few of the records by which compliance could be shown. We propose a set of such records, identify what a single laboratory can and cannot reasonably do, and set out the questions the profession has not yet answered.
- 7 April 2025
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 63 (9) , 1736-1741
Prevalence and re-evaluation of macroprolactinemia in hyperprolactinemic patients: a retrospective study in the Turkish population
Objectives: This study aimed to investigate the prevalence of macroprolactinemia and the changes in hyperprolactinemia status over time among hyperprolactinemic patients in the Turkish population. Methods: A retrospective study was conducted on 3,013 patient records from a central university hospital between October 2023 and October 2024. Of these, 634 hyperprolactinemic samples (Prolactin >15.2 μg/L in males, >23.3 μg/L in females) were analyzed using polyethylene glycol (PEG) precipitation method. Post-PEG prolactin levels were measured using electrochemiluminescence immunoassay, with the recovery percentage (R%) calculated as the ratio of prolactin post-PEG precipitation to total prolactin, where R% values below 40 % were indicative of macroprolactinemia. The change in R% values was analyzed in 63 hyperprolactinemic patients who underwent restesting. Results: Macroprolactinemia prevalence was found as 5.67 % of hyperprolactinemic patients with no macroprolactinemia cases observed at PRL levels above 85.40 μg/L. Male patients had significantly higher R% values than females (p=0.003). In the gray zone (R%: 40–60), 29.03 % of patients were classified as truly hyperprolactinemic. Repeated tests after an average of four months showed stable R% values in most cases, with only two patients changing classification between macroprolactinemia and true hyperprolactinemia. Conclusions: The prevalence of macroprolactinemia in hyperprolactinemic Turkish patients was relatively low. As prolactin values increase, true hyperprolactinemia is more commenly observed instead of macroprolactinemia. Short-term retesting for macroprolactinemia may not be necessary unless clinical conditions change significantly. Accurate diagnosis requires method-specific cutoffs and further prospective studies using gold-standard methods like gel filtration chromatography.
- 7 April 2025
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 63 (9) , 1736-1741
Prevalence and re-evaluation of macroprolactinemia in hyperprolactinemic patients: a retrospective study in the Turkish population
Objectives: This study aimed to investigate the prevalence of macroprolactinemia and the changes in hyperprolactinemia status over time among hyperprolactinemic patients in the Turkish population. Methods: A retrospective study was conducted on 3,013 patient records from a central university hospital between October 2023 and October 2024. Of these, 634 hyperprolactinemic samples (Prolactin >15.2 μg/L in males, >23.3 μg/L in females) were analyzed using polyethylene glycol (PEG) precipitation method. Post-PEG prolactin levels were measured using electrochemiluminescence immunoassay, with the recovery percentage (R%) calculated as the ratio of prolactin post-PEG precipitation to total prolactin, where R% values below 40 % were indicative of macroprolactinemia. The change in R% values was analyzed in 63 hyperprolactinemic patients who underwent restesting. Results: Macroprolactinemia prevalence was found as 5.67 % of hyperprolactinemic patients with no macroprolactinemia cases observed at PRL levels above 85.40 μg/L. Male patients had significantly higher R% values than females (p=0.003). In the gray zone (R%: 40–60), 29.03 % of patients were classified as truly hyperprolactinemic. Repeated tests after an average of four months showed stable R% values in most cases, with only two patients changing classification between macroprolactinemia and true hyperprolactinemia. Conclusions: The prevalence of macroprolactinemia in hyperprolactinemic Turkish patients was relatively low. As prolactin values increase, true hyperprolactinemia is more commenly observed instead of macroprolactinemia. Short-term retesting for macroprolactinemia may not be necessary unless clinical conditions change significantly. Accurate diagnosis requires method-specific cutoffs and further prospective studies using gold-standard methods like gel filtration chromatography.
- Open Access
- 26 September 2022
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
- Vol. 4 (3) , 172-177
Gardnerella vaginalis: Is it an Underestimated Cause of Urinary Symptoms in Males?
Objective: This study aimed t o investigate the detection rate of Gardnerella vaginalis by multiplex PCR test in the genitourinary samples of male patients with suspected urethritis and related symptoms. Materials and Methods: A total of 144 male patients who presented to our department between February 2021 and October 2021, either with urinary symptoms or concerns following unprotected sex, were included in the study. A total of 128 (88.9%) first-void urine samples, 15 (10.4%) urethral swabs, and one (0.7%) semen sample were obtained. NeoPlex STI-14 Detection Multiplex PCR Kit (GeneMatrix Inc. Seongnam, South Korea) was used to investigate any of the following pathogens: Candida albicans, Chlamydia trachomatis, G. vaginalis, Mycoplasma genitalium, Mycoplasma hominis, Neisseria gonorrhoeae, Trichomonas vaginalis, Ureaplasma parvum, Ureaplasma urealyticum, herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2), Treponema pallidum, Streptococcus agalactiae, and Haemophilus ducreyi. The patients with positive results for G. vaginalis were retrospectively analyzed. Results: The patients’ median age was 37 (range: 21 to 71 years old). G. vaginalis was the most frequently detected microorganism (n=23; 15.9%). Other microorganisms found in order of frequency were U. urealyticum (n=19; 13.2%), U. parvum (n=15; 10.4%), C. trachomatis (n=11; 7.6%), M. genitalium (n=8; 5.6%), HSV-2 (n= 7; 4.9%), N. gonorrhoeae (n=6; 4.2), HSV-1 (n=2; 1.4%), M. hominis (n=1, 0.7%), and C. albicans (n=1, 0.7%). Fifteen patients (65%) were positive for one or two microbial agents together with G. vaginalis, while in eight patients (35%), G. vaginalis was the only isolated agent. Six of these eight patients and 14 of the remaining 15 were symptomatic. Conclusion: With the introduction of multiplex PCR tests, including those for G. vaginalis, we can expect a higher detection rate of these species of bacteria in male genitourinary samples, which could be the cause of unexplained urinary/urethral symptoms. Keywords: Gardnerella vaginalis, male, polymerase chain reaction, urethritis
- 26 September 2022
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
- Vol. 4 (3) , 172-177
Open AccessGardnerella vaginalis: Is it an Underestimated Cause of Urinary Symptoms in Males?
Objective: This study aimed t o investigate the detection rate of Gardnerella vaginalis by multiplex PCR test in the genitourinary samples of male patients with suspected urethritis and related symptoms. Materials and Methods: A total of 144 male patients who presented to our department between February 2021 and October 2021, either with urinary symptoms or concerns following unprotected sex, were included in the study. A total of 128 (88.9%) first-void urine samples, 15 (10.4%) urethral swabs, and one (0.7%) semen sample were obtained. NeoPlex STI-14 Detection Multiplex PCR Kit (GeneMatrix Inc. Seongnam, South Korea) was used to investigate any of the following pathogens: Candida albicans, Chlamydia trachomatis, G. vaginalis, Mycoplasma genitalium, Mycoplasma hominis, Neisseria gonorrhoeae, Trichomonas vaginalis, Ureaplasma parvum, Ureaplasma urealyticum, herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2), Treponema pallidum, Streptococcus agalactiae, and Haemophilus ducreyi. The patients with positive results for G. vaginalis were retrospectively analyzed. Results: The patients’ median age was 37 (range: 21 to 71 years old). G. vaginalis was the most frequently detected microorganism (n=23; 15.9%). Other microorganisms found in order of frequency were U. urealyticum (n=19; 13.2%), U. parvum (n=15; 10.4%), C. trachomatis (n=11; 7.6%), M. genitalium (n=8; 5.6%), HSV-2 (n= 7; 4.9%), N. gonorrhoeae (n=6; 4.2), HSV-1 (n=2; 1.4%), M. hominis (n=1, 0.7%), and C. albicans (n=1, 0.7%). Fifteen patients (65%) were positive for one or two microbial agents together with G. vaginalis, while in eight patients (35%), G. vaginalis was the only isolated agent. Six of these eight patients and 14 of the remaining 15 were symptomatic. Conclusion: With the introduction of multiplex PCR tests, including those for G. vaginalis, we can expect a higher detection rate of these species of bacteria in male genitourinary samples, which could be the cause of unexplained urinary/urethral symptoms. Keywords: Gardnerella vaginalis, male, polymerase chain reaction, urethritis
- 14 September 2021
- Published by Wiley in Pediatric Transplantation
- Vol. 25 (7) , e14142
Improving the urine spot protein/creatinine ratio by the estimated creatinine excretion to predict proteinuria in pediatric kidney transplant recipients
Background: Since the daily creatinine excretion rate (CER) is directly affected by muscle mass, which varies with age, gender, and body weight, using the spot protein/creatinine ratio (Spot P/Cr) follow‐up of proteinuria may not always be accurate. Estimated creatinine excretion rate (eCER) can be calculated from spot urine samples with formulas derived from anthropometric factors. Multiplying Spot P/Cr by eCER gives the estimated protein excretion rate (ePER). We aimed to determine the most applicable equation for predicting daily CER and examine whether ePER values acquired from different equations can anticipate measured 24 h urine protein (m24 h UP) better than Spot P/Cr in pediatric kidney transplant recipients.Methods: This study enrolled 23 children with kidney transplantation. To estimate m24 h UP, we calculated eCER and ePER values with three formulas adapted to children (Cockcroft‐Gault, Ghazali‐Barratt, and Hellerstein). To evaluate the accuracy of the methods, Passing‐Bablok and Bland‐Altman analysis were used.Results: A statistically significant correlation was found between m24 h UP and Spot P/Cr (p < .001, r = 0.850), and the correlation was enhanced by multiplying the Spot P/Cr by the eCER equations. The average bias of the ePER formulas adjusted by the Cockcroft‐Gault, Ghazali‐Barratt, and Hellerstein equations were −0.067, 0.031, and 0.064 g/day, respectively, whereas the average bias of Spot P/Cr was −0.270 g/day obtained by the Bland‐Altman graphics.Conclusion: Using equations to estimate eCER may improve the accuracy and reduce the spot urine samples’ bias in pediatric kidney transplantation recipients. Further studies in larger populations are needed for ePER reporting to be ready for clinical practice.
- 14 September 2021
- Published by Wiley in Pediatric Transplantation
- Vol. 25 (7) , e14142
Improving the urine spot protein/creatinine ratio by the estimated creatinine excretion to predict proteinuria in pediatric kidney transplant recipients
Background: Since the daily creatinine excretion rate (CER) is directly affected by muscle mass, which varies with age, gender, and body weight, using the spot protein/creatinine ratio (Spot P/Cr) follow‐up of proteinuria may not always be accurate. Estimated creatinine excretion rate (eCER) can be calculated from spot urine samples with formulas derived from anthropometric factors. Multiplying Spot P/Cr by eCER gives the estimated protein excretion rate (ePER). We aimed to determine the most applicable equation for predicting daily CER and examine whether ePER values acquired from different equations can anticipate measured 24 h urine protein (m24 h UP) better than Spot P/Cr in pediatric kidney transplant recipients.Methods: This study enrolled 23 children with kidney transplantation. To estimate m24 h UP, we calculated eCER and ePER values with three formulas adapted to children (Cockcroft‐Gault, Ghazali‐Barratt, and Hellerstein). To evaluate the accuracy of the methods, Passing‐Bablok and Bland‐Altman analysis were used.Results: A statistically significant correlation was found between m24 h UP and Spot P/Cr (p < .001, r = 0.850), and the correlation was enhanced by multiplying the Spot P/Cr by the eCER equations. The average bias of the ePER formulas adjusted by the Cockcroft‐Gault, Ghazali‐Barratt, and Hellerstein equations were −0.067, 0.031, and 0.064 g/day, respectively, whereas the average bias of Spot P/Cr was −0.270 g/day obtained by the Bland‐Altman graphics.Conclusion: Using equations to estimate eCER may improve the accuracy and reduce the spot urine samples’ bias in pediatric kidney transplantation recipients. Further studies in larger populations are needed for ePER reporting to be ready for clinical practice.